FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2345312409> ?p ?o ?g. }

• W2345312409 endingPage "2556" @default.
• W2345312409 startingPage "2556" @default.
• W2345312409 abstract "2556 Background: EZN-2208 is a water-soluble, polyethylene glycol (PEG) conjugate of SN38 that is active in solid tumors and lymphoma preclinical models, including an in vivo CPT-11-resistant tumor model. EZN-2208 accumulates in tumors, where it releases SN38. Methods: Pts with advanced solid tumors were enrolled to determine the safety, tolerability, PK, maximum tolerated dose, recommended dose, and preliminary evidence of antitumor activity of EZN-2208 administered as a 1-hour intravenous infusion every 3 weeks in a 3+3 escalating dose design. Pts homozygous for UGT1A1*28 were eligible after safety was established in non-homozygous pts. Dose escalation was based on drug-related toxicities observed during the first cycle. Plasma concentrations of EZN-2208 and SN38 were determined by HPLC using fluorescence detection. Pharmacokinetic parameters were estimated using a non-compartmental model analysis. Results: Ten pts (2 males; median age = 59 yrs [34–79 yrs]) were treated at doses of 1.25 (3 pts), 2.5 (3 pts), 5.0 (3 pts), and 10 (1 pt) mg/m2. All 10 pts were pretreated (median number of prior regimens = 5). Tumor types included colorectal (7 pts), gastric (1 pt), anal (1 pt), and breast (1 pt) cancers. Adverse events included grade 2 fatigue and grade 2 neutropenia. No dose-limiting toxicities were observed. Stable disease was observed in 3 pts; 2 of the pts had previously progressed while receiving irinotecan. Plasma PK in the first 3 cohorts (9 pts) is provided in the table below. Conclusions: EZN-2208, a novel agent, was well tolerated in pretreated pts with solid tumors. A qualitative assessment of the data indicates a rough proportionality in AUC vs dose. PK data demonstrated high AUC and prolonged exposure to SN38. Dose escalation is ongoing. Dosea (mg/m2) EZN-2208 b SN38 b Cmaxa (μg/mL) AUC(0-∞)a (h·μg/mL) Terminal t½ (h) Cmax(ng/mL) AUC(0-t)c (h·μg/mL) 1.25 22.4±5.8 645±152 30.1±6.3 32.9±42.1 504±393 2.5 26.1±15.9 891±713 43.8±20.2 14.8±8.0 569±337 5.0 40.6±14.7 1,414±559 53.7±20.7 54.9±33.6 1,026±229 a = SN38 equivalents; b = Mean ± standard deviation; c = AUC(0-t), t is time of last measurable concentration. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Enzon Pharmaceuticals Enzon Pharmaceuticals Enzon Pharmaceuticals" @default.
• W2345312409 created "2016-06-24" @default.
• W2345312409 creator A5005436649 @default.
• W2345312409 creator A5027363088 @default.
• W2345312409 creator A5029455802 @default.
• W2345312409 creator A5036972230 @default.
• W2345312409 creator A5053481267 @default.
• W2345312409 creator A5054253206 @default.
• W2345312409 creator A5054253771 @default.
• W2345312409 creator A5064321971 @default.
• W2345312409 creator A5071506606 @default.
• W2345312409 creator A5082431743 @default.
• W2345312409 date "2008-05-20" @default.
• W2345312409 modified "2023-10-14" @default.
• W2345312409 title "Clinical pharmacokinetics (PK) of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: A phase I, first-in-human, dose-escalation study" @default.
• W2345312409 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.2556" @default.
• W2345312409 hasPublicationYear "2008" @default.
• W2345312409 type Work @default.
• W2345312409 sameAs 2345312409 @default.
• W2345312409 citedByCount "9" @default.
• W2345312409 countsByYear W23453124092012 @default.
• W2345312409 countsByYear W23453124092013 @default.
• W2345312409 countsByYear W23453124092014 @default.
• W2345312409 countsByYear W23453124092015 @default.
• W2345312409 crossrefType "journal-article" @default.
• W2345312409 hasAuthorship W2345312409A5005436649 @default.
• W2345312409 hasAuthorship W2345312409A5027363088 @default.
• W2345312409 hasAuthorship W2345312409A5029455802 @default.
• W2345312409 hasAuthorship W2345312409A5036972230 @default.
• W2345312409 hasAuthorship W2345312409A5053481267 @default.
• W2345312409 hasAuthorship W2345312409A5054253206 @default.
• W2345312409 hasAuthorship W2345312409A5054253771 @default.
• W2345312409 hasAuthorship W2345312409A5064321971 @default.
• W2345312409 hasAuthorship W2345312409A5071506606 @default.
• W2345312409 hasAuthorship W2345312409A5082431743 @default.
• W2345312409 hasConcept C112705442 @default.
• W2345312409 hasConcept C121608353 @default.
• W2345312409 hasConcept C126322002 @default.
• W2345312409 hasConcept C197934379 @default.
• W2345312409 hasConcept C2777063308 @default.
• W2345312409 hasConcept C2778375690 @default.
• W2345312409 hasConcept C2780259306 @default.
• W2345312409 hasConcept C29730261 @default.
• W2345312409 hasConcept C526805850 @default.
• W2345312409 hasConcept C71924100 @default.
• W2345312409 hasConcept C90924648 @default.
• W2345312409 hasConcept C98274493 @default.
• W2345312409 hasConceptScore W2345312409C112705442 @default.
• W2345312409 hasConceptScore W2345312409C121608353 @default.
• W2345312409 hasConceptScore W2345312409C126322002 @default.
• W2345312409 hasConceptScore W2345312409C197934379 @default.
• W2345312409 hasConceptScore W2345312409C2777063308 @default.
• W2345312409 hasConceptScore W2345312409C2778375690 @default.
• W2345312409 hasConceptScore W2345312409C2780259306 @default.
• W2345312409 hasConceptScore W2345312409C29730261 @default.
• W2345312409 hasConceptScore W2345312409C526805850 @default.
• W2345312409 hasConceptScore W2345312409C71924100 @default.
• W2345312409 hasConceptScore W2345312409C90924648 @default.
• W2345312409 hasConceptScore W2345312409C98274493 @default.
• W2345312409 hasIssue "15_suppl" @default.
• W2345312409 hasLocation W23453124091 @default.
• W2345312409 hasOpenAccess W2345312409 @default.
• W2345312409 hasPrimaryLocation W23453124091 @default.
• W2345312409 hasRelatedWork W1996694250 @default.
• W2345312409 hasRelatedWork W2010640916 @default.
• W2345312409 hasRelatedWork W2037576960 @default.
• W2345312409 hasRelatedWork W2074207917 @default.
• W2345312409 hasRelatedWork W2977802423 @default.
• W2345312409 hasRelatedWork W3003305233 @default.
• W2345312409 hasRelatedWork W3173651342 @default.
• W2345312409 hasRelatedWork W4205587618 @default.
• W2345312409 hasRelatedWork W4296087748 @default.
• W2345312409 hasRelatedWork W4366822339 @default.
• W2345312409 hasVolume "26" @default.
• W2345312409 isParatext "false" @default.
• W2345312409 isRetracted "false" @default.
• W2345312409 magId "2345312409" @default.
• W2345312409 workType "article" @default.